• 1
    Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010;24:6586.
  • 2
    Matthay KK. Targeted isotretinoin in neuroblastoma: kinetics, genetics or absorption. Clin Cancer Res 2013;19:311313.
  • 3
    Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:111116.
  • 4
    Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:20316.
  • 5
    Gamble LD, Hogarty MD, Liu X, et al. Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. Front Oncol 2012;2:162. doi: 10.3389/fonc.2012.00162. Epub 2012 Nov 16.
  • 6
    Bello-Fernandez C, Packham G, et al. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90: 78048.
  • 7
    Wagner AJ, Meyers C, Laimins LA, et al. c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ 1993;4:87983.
  • 8
    Lutz W, Stohr M, Schurmann J, et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:80312.
  • 9
    Rounbehler RJ, Li W, Hall MA, et al. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 2009;69:54753.
  • 10
    Geerts D, Koster J, Albert D, et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 2010;126:201224.
  • 11
    Wallick CJ, Gamper I, Thorne M, et al. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 2005;24:560618.
  • 12
    Bachmann AS, Geerts D, Sholler G. Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention In: Hayat E, editor. Pediatric Cancer: Diagnosis, Therapy, and Prognosis: Neuroblastoma. Germany: Springer Company, 2012. p. 91103.
  • 13
    Meyskens FL Jr, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:94551. Review.
  • 14
    Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000:387884.
  • 15
    Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003;9:98190.
  • 16
    Meyskens FL Jr, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008;1:3238.
  • 17
    Bachmann AS, Levin VA. Clinical applications of polyamine-based therapeutics. In: Woster PM, Casero RA Jr, editors. Polyamine drug discovery. Germany: Royal Society of Chemistry, 2012. p. 257276.
  • 18
    Sarhan S, Knodgen B, Seiler N. The gastrointestinal tract as polyamine source for tumor growth. Anticancer Res 1989;9: 21524.
  • 19
    Chen Y, Weeks RS, Burns MR, et al. Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int J Cancer 2006;118:23449.
  • 20
    Devens BH, Weeks RS, Burns MR, et al. Polyamine depletion therapy in prostate cancer. Prostate Cancer Prostatic Dis 2000;3:2759.
  • 21
    Weeks RS, Vanderwerf SM, Carlson CL, et al. Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO. Exp Cell Res 2000;261:293302.
  • 22
    Burns MR, Graminski GF, Weeks RS, et al. Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor. J Med Chem 2009;52:198393.
  • 23
    Seiler N, Knodgen B. High-performance liquid chromatographic procedure for the simultaneous determination of the natural polyamines and their monoacetyl derivatives. J Chromatogr 1980;221:22735.
  • 24
    Matsuo T, Thiele CJ. p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 1998;16:333743.
  • 25
    Galderisi U, Di Bernardo G, Cipollaro M, et al. Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein. J Cell Biochem 1999;74:31322.
  • 26
    Galderisi U, Jori FP, Giordano A. Cell cycle regulation and neural differentiation. Oncogene 2003;22:520819.
  • 27
    Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer Lett 2003;197:12530. Review.
  • 28
    Koomoa DL, Yco LP, Borsics T, et al. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 2008;68:982531.
  • 29
    Koomoa DL, Geerts D, Lange I, et al. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol 2013;42:121928.
  • 30
    Claverie N, Mamont PS. Comparative antitumor properties in rodents of irreversible inhibitors of l-ornithine decarboxylase, used as such or as prodrugs. Cancer Res 1989;49:446671.
  • 31
    Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect, Parts 1 and 2: selective enzyme inhibitor and structural analogues and derivatives. Curr Drug Targets 2003;4:53785.